Insulin Receptor Expression and Activity in the Brains of Nondiabetic Sporadic Alzheimer's Disease Cases

We investigated the contents of the insulin receptor-beta subunit (IRβ) and [Tyr1162/1163]-phosphorylated IRβ as surrogate indices of total IR content and IR activation in postmortem hippocampal formation brain specimens from nondiabetic sporadic Alzheimer's disease (AD) cases. We found no significant changes in the brain contents of total IRβ or [Tyr1162/1163]-phosphorylated IRβ, suggesting normal IR content and activation in the brains of nondiabetic sporadic AD cases. Moreover, total IRβ and [Tyr1162/1163]-phosphorylated IRβ levels in the hippocampal formation are not correlated with the severity of amyloid or tau-neuropathology. Exploring the regulation of glycogen synthase kinase 3 (GSK3) α/β, key IR-signaling components, we observed significantly lower levels of total GSK3 α/β in brain specimens from nondiabetic AD cases, suggesting that impaired IR signaling mechanisms might contribute to the onset and/or progression of AD dementia. Outcomes from our study support the development of insulin-sensitizing therapeutic strategies to stimulate downstream IR signaling in nondiabetic AD cases.

[1]  Ying Liu,et al.  Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes , 2011, The Journal of pathology.

[2]  C. Mammucari,et al.  Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models , 2011, Skeletal Muscle.

[3]  Rosemary O’Connor,et al.  Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling , 2010, Neurobiology of Aging.

[4]  A. Ray,et al.  Glycogen synthase kinase 3: more than a namesake , 2009, British journal of pharmacology.

[5]  A. Erol.  Unraveling the molecular mechanisms behind the metabolic basis of sporadic Alzheimer's disease. , 2008, Journal of Alzheimer's disease : JAD.

[6]  L. Wilkins.  Intranasal insulin improves cognition and modulates β-amyloid in early AD , 2008, Neurology.

[7]  V. Haroutunian,et al.  Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology , 2008, Neurology.

[8]  Simon Lovestone,et al.  The GSK3 hypothesis of Alzheimer's disease , 2008, Journal of neurochemistry.

[9]  A. Clerk,et al.  Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis , 2008, British journal of pharmacology.

[10]  Ling Li,et al.  Intake of Sucrose-sweetened Water Induces Insulin Resistance and Exacerbates Memory Deficits and Amyloidosis in a Transgenic Mouse Model of Alzheimer Disease* , 2007, Journal of Biological Chemistry.

[11]  Christian Hölscher,et al.  Common pathological processes in Alzheimer disease and type 2 diabetes: A review , 2007, Brain Research Reviews.

[12]  Suzanne Craft,et al.  Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. , 2007, Current Alzheimer research.

[13]  G. Landreth.  Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. , 2007, Current Alzheimer research.

[14]  J. Youngren.  Regulation of insulin receptor function , 2007, Cellular and Molecular Life Sciences.

[15]  K. Leroy,et al.  Increased level of active GSK‐3β in Alzheimer’s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration , 2007, Neuropathology and applied neurobiology.

[16]  L. Garcia-Segura,et al.  Cross-Talk between IGF-I and Estradiol in the Brain: Focus on Neuroprotection , 2007, Neuroendocrinology.

[17]  M. White.  Regulating insulin signaling and β-cell function through IRS proteinsThis paper is one of a selection of papers published in this Special Issue, entitled Second Messengers and Phosphoproteins—12th International Conference. , 2006 .

[18]  G. Ramakers,et al.  Insulin signaling in the central nervous system: Learning to survive , 2006, Progress in Neurobiology.

[19]  R. Jope,et al.  AMP-activated protein kinase (AMPK) activating agents cause dephosphorylation of Akt and glycogen synthase kinase-3. , 2006, Biochemical pharmacology.

[20]  Chiranjib Chakraborty,et al.  Biochemical and molecular basis of insulin resistance. , 2006, Current protein & peptide science.

[21]  A. Levey,et al.  Glycogen synthase kinase 3β and Alzheimer’s disease: pathophysiological and therapeutic significance , 2006, Cellular and Molecular Life Sciences CMLS.

[22]  G. Schellenberg,et al.  Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype , 2006, Neurobiology of Aging.

[23]  C. Kahn,et al.  Critical nodes in signalling pathways: insights into insulin action , 2006, Nature Reviews Molecular Cell Biology.

[24]  M. Sajan,et al.  Insulin signalling downstream of protein kinase B is potentiated by 5′AMP-activated protein kinase in rat hearts in vivo , 2005, Diabetologia.

[25]  R. Ravid,et al.  Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology , 2005, Journal of neurochemistry.

[26]  K. Davis,et al.  Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.

[27]  Jan Born,et al.  Intranasal insulin improves memory in humans , 2004, Psychoneuroendocrinology.

[28]  Patrick R Hof,et al.  Diet‐induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  C. Kahn,et al.  Role for neuronal insulin resistance in neurodegenerative diseases. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Christina A. Wilson,et al.  GSK-3α regulates production of Alzheimer's disease amyloid-β peptides , 2003, Nature.

[31]  L. Hersh,et al.  Amyloid-β peptide levels in brain are inversely correlated with insulysin activity levels in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  H. Manji,et al.  Post-mortem Interval Effects on the Phosphorylation of Signaling Proteins , 2003, Neuropsychopharmacology.

[33]  R. Friedland,et al.  Interactions of apolipoprotein E genotype and dietary fat intake of healthy older persons during mid-adult life. , 2003, Metabolism: clinical and experimental.

[34]  M. Birnbaum,et al.  Role of Akt/protein kinase B in metabolism , 2002, Trends in Endocrinology & Metabolism.

[35]  G. Downey,et al.  Insulin, insulin-like growth factor-I, and platelet-derived growth factor activate extracellular signal-regulated kinase by distinct pathways in muscle cells. , 2001, Biochemical and biophysical research communications.

[36]  P. Greengard,et al.  Stimulation of β-Amyloid Precursor Protein Trafficking by Insulin Reduces Intraneuronal β-Amyloid and Requires Mitogen-Activated Protein Kinase Signaling , 2001, The Journal of Neuroscience.

[37]  G. Rauch,et al.  Cardiovascular and Other Risk Factors for Alzheimer's Disease and Vascular Dementia , 2000, Annals of the New York Academy of Sciences.

[38]  K. Davis,et al.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.

[39]  M. Laakso,et al.  Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[40]  K. Davis,et al.  Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. , 1999, Archives of neurology.

[41]  J. Tuomilehto,et al.  Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial , 1998, The Lancet.

[42]  K. Davis,et al.  Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. , 1998, Archives of neurology.

[43]  L. Hansson,et al.  Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. , 1998, Hypertension.

[44]  E. Kokmen,et al.  The risk of dementia among persons with diabetes mellitus: a population-based cohort study. , 1997 .

[45]  S. Mirra.  The CERAD Neuropathology Protocol and Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease: A Commentary , 1997, Neurobiology of Aging.

[46]  A. Hofman,et al.  Insulin and Cognitive Function in an Elderly Population: The Rotterdam Study , 1997, Diabetes Care.

[47]  P. O'Brien,et al.  Risk of dementia among persons with diabetes mellitus: a population-based cohort study. , 1997, American journal of epidemiology.

[48]  E. Masliah,et al.  Glycogen synthase kinase 3 alteration in Alzheimer disease is related to neurofibrillary tangle formation. , 1996, Molecular and chemical neuropathology.

[49]  B. Lernfelt,et al.  15-year longitudinal study of blood pressure and dementia , 1996, The Lancet.

[50]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[51]  O. Rosen.  After insulin binds. , 1987, Science.

[52]  A. Hirano,et al.  A COMPARATIVE STUDY OF MODIFIED BIELSCHOWSKY, BODIAN AND THIOFLAVIN S STAINS ON ALZHEIMER'S NEUROFIBRILLARY TANGLES , 1986, Neuropathology and applied neurobiology.

[53]  Akihiko Takashima,et al.  GSK-3 is essential in the pathogenesis of Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[54]  Ming Tong,et al.  Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[55]  M. Hüll,et al.  Disease-modifying therapies in Alzheimer's disease: how far have we come? , 2006, Drugs.

[56]  J. Wands,et al.  Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. , 2005, Journal of Alzheimer's disease : JAD.

[57]  J. Wands,et al.  Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? , 2005, Journal of Alzheimer's disease : JAD.

[58]  G. Schellenberg,et al.  Reduced Hippocampal Insulin-Degrading Enzyme in Late-Onset Alzheimer's Disease Is Associated with the Apolipoprotein E-ε4 Allele , 2003 .

[59]  W. Grant.  Dietary links to Alzheimer's disease: 1999 update. , 1999, Journal of Alzheimer's disease : JAD.

[60]  K. Jellinger,et al.  Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease , 1998, Journal of Neural Transmission.

[61]  W. Grant.  Dietary Links to Alzheimer's Disease , 1997 .